AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1999, p. 2320-2322, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) against Bacteroides fragilis Group: Comparison with the Activities of 14 Other Agents

Carmen Betriu,* María Gómez, M. Luisa Palau, Ana Sánchez, and Juan J. Picazo

Servicio de Microbiología Clínica, Hospital Clínico San Carlos, 28040 Madrid, Spain

Received 11 March 1999/Returned for modification 13 May 1999/Accepted 29 June 1999

The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the beta -lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 µg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 µg/ml, respectively.

* Corresponding author. Mailing address: Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. Phone: 341 3303486. Fax: 341 3303478. E-mail: cbetriu{at}efd.net.

Antimicrobial Agents and Chemotherapy, September 1999, p. 2320-2322, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.